About

The Solo-Dex Fascile Continuous Peripheral Nerve Block (cPNB) products are on track to become the new standard of care for regional anesthesia. In 2011, just as ultrasound visualization was becoming widely available, our founding anesthesiologists Drs. Sundar Rajendran and Dan Kopacz understood the need for improvement. Their vision: regional anesthesia would proliferate when its fast, simple to use, reliable, and stays in place. They invented and patented over-the-needle novel catheter designs to provide precise, sustainable, and regulatable acute pain management. They knew that their colleagues would only embrace their new catheter if it was substantially easier to place than anything else.

6,000 patients later, Solo-Dex innovations were introduced to the market. Solo-Dex products arrived just as just surging post-surgical opioid use exposed a need for an alternative approach that would manage post-surgical acute pain for days of recovery without oral opioid therapy. In addition, the Covid 19 pandemic ushered in the need to reduce airway manipulation in the surgical suite and decrease the duration and discomfort of recovery from general anesthesia.

In 2020, a leading MedTech innovator, Steve Eror, joined as CEO to take the Solo-Dex innovation around the world. Today, Solo-Dex proprietary products are sold in the US, the European Union, India, Brazil, the Middle East.

Our mission; to assist patients and their providers avoid the risks associated with general anesthesia, trim hospital recovery time and discomfort, accelerate hospital discharge time, and reduce or eliminate the use of opioids during home recovery. For hospitals and surgical centers, clinical costs are reduced, and patient satisfaction is increased. Surgical staff exposure to infection, like Covid-19, is limited with our technology because unlike general anesthesia, the patient’s airway is not manipulated.